OpenAI offers GPT-Rosalind-6 for biology research through trusted access, treating it as High in biology and Critical in cyber

OpenAI · System card

Read the source (opens in a new tab)
What happened
OpenAI published a system card addendum on October 30, 2026 for GPT-Rosalind-6, a biology and drug discovery model that uses GPT-6 Astra's weights and is available only to approved customers.
Key points
  • Rosalind "has fewer refusals on dual-use biological queries" and supports some dual-use topics GPT-6 Astra may refuse, while still refusing requests for biological weaponization.
  • Rated High in biological and chemical capability, below Critical: adjusted for refusals, it exceeds indicative High thresholds on three of four evaluations and meets none of four Critical thresholds.
  • It takes GPT-6 Astra's Critical cybersecurity rating and below-High AI self-improvement rating, and adds "a more conservative cyber refusal boundary."
  • Access rules match GPT-Rosalind-5.5's and do not widen eligibility beyond earlier announcements such as the Rosalind Academic Plan; outputs need human review before informing experiments, and OpenAI can revoke access for misuse.
Evidence
Company system card addendum. OpenAI says its biology evaluations test specific capabilities, not the full ability to cause biological harm, and that its Critical thresholds are preliminary estimates.
Uncertain
OpenAI does not publish the details of its biosecurity red-teaming of its misuse monitoring and enforcement, and says it is still repeating that test for GPT-Rosalind-6 now that it is deployed.

See it in the latest record